Growth Factor and Signaling Pathways and Their Relevance to Prostate Cancer Therapeutics

Overview

Journal Cancer Metastasis Rev

Specialty Oncology

Date 2014 Jan 10

PMID 24402967

Citations 23

Authors

Jocelyn L Wozney

Emmanuel S Antonarakis

Affiliations

Soon will be listed here.

Abstract

Treatments that target the androgen axis represent an effective strategy for patients with advanced prostate cancer, but the disease remains incurable and new therapeutic approaches are necessary. Significant advances have recently occurred in our understanding of the growth factor and signaling pathways that are active in prostate cancer. In conjunction with this, many new targeted therapies with sound preclinical rationale have entered clinical development and are being tested in men with castration-resistant prostate cancer. Some of the most relevant pathways currently being exploited for therapeutic gain are HGF/c-Met signaling, the PI3K/AKT/mTOR pathway, Hedgehog signaling, the endothelin axis, Src kinase signaling, the IGF pathway, and angiogenesis. Here, we summarize the biological basis for the use of selected targeted agents and the results from available clinical trials of these drugs in men with prostate cancer.

Citing Articles

Targeting cytokine and chemokine signaling pathways for cancer therapy.

Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K Signal Transduct Target Ther. 2024; 9(1):176.

PMID: 39034318 PMC: 11275440. DOI: 10.1038/s41392-024-01868-3.

The nerve growth factor-delivered signals in prostate cancer and its associated microenvironment: when the dialogue replaces the monologue.

Di Donato M, Giovannelli P, Migliaccio A, Castoria G Cell Biosci. 2023; 13(1):60.

PMID: 36941697 PMC: 10029315. DOI: 10.1186/s13578-023-01008-4.

Inactivation of Wnt-LRP5 signaling suppresses the proliferation and migration of ovarian cancer cells.

Hong J, Xie Z, Yang Z, Yang F, Liao H, Rao S Transl Cancer Res. 2022; 10(5):2277-2285.

PMID: 35116545 PMC: 8797788. DOI: 10.21037/tcr-20-3462.

Effects of meditation compared to music listening on biomarkers in breast cancer survivors with cognitive complaints: secondary outcomes of a pilot randomized control trial.

Henneghan A, Fico B, Wright M, Kesler S, Harrison M Explore (NY). 2021; 18(6):657-662.

PMID: 34802955 PMC: 9085959. DOI: 10.1016/j.explore.2021.10.011.

Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells.

Uddin M, Li Y, Khan H, Muqbil I, Aboukameel A, Sexton R Int J Mol Sci. 2021; 22(13).

PMID: 34206543 PMC: 8268282. DOI: 10.3390/ijms22136676.

References

Kim T, Lee J, Hwang T, Kang C, Choi Y . Hedgehog signaling protein expression and its association with prognostic parameters in prostate cancer: a retrospective study from the view point of new 2010 anatomic stage/prognostic groups. J Surg Oncol. 2011; 104(5):472-9. DOI: 10.1002/jso.21988. View

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

Kim J, Tang J, Gong R, Kim J, Lee J, Clemons K . Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010; 17(4):388-99. PMC: 4039177. DOI: 10.1016/j.ccr.2010.02.027. View

Knudsen B, Edlund M . Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res. 2004; 91:31-67. DOI: 10.1016/S0065-230X(04)91002-0. View

Peters S, Adjei A . MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol. 2012; 9(6):314-26. DOI: 10.1038/nrclinonc.2012.71. View

Yap T, Olmos D, Brunetto A, Tunariu N, Barriuso J, Riisnaes R . Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol. 2011; 29(10):1271-9. DOI: 10.1200/JCO.2010.31.0367. View

Beardsley E, Hotte S, North S, Ellard S, Winquist E, Kollmannsberger C . A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. Invest New Drugs. 2011; 30(4):1652-9. DOI: 10.1007/s10637-011-9722-5. View

Yap T, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K . First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol. 2011; 29(35):4688-95. DOI: 10.1200/JCO.2011.35.5263. View

Michaelson M, Oudard S, Ou Y, Sengelov L, Saad F, Houede N . Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol. 2013; 32(2):76-82. DOI: 10.1200/JCO.2012.48.5268. View

10.

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

11.

Posadas E, Gulley J, Arlen P, Trout A, Parnes H, Wright J . A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther. 2005; 4(10):1133-7. DOI: 10.4161/cbt.4.10.2064. View

12.

Scagliotti G, Novello S, von Pawel J . The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev. 2013; 39(7):793-801. DOI: 10.1016/j.ctrv.2013.02.001. View

13.

Ryan C, Rosenthal M, Ng S, Alumkal J, Picus J, Gravis G . Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2012; 19(1):215-24. DOI: 10.1158/1078-0432.CCR-12-2605. View

14.

Smith D, Smith M, Sweeney C, Elfiky A, Logothetis C, Corn P . Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2012; 31(4):412-9. PMC: 4110249. DOI: 10.1200/JCO.2012.45.0494. View

15.

Aftab B, Dobromilskaya I, Liu J, Rudin C . Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res. 2011; 71(21):6764-72. PMC: 3206167. DOI: 10.1158/0008-5472.CAN-11-0691. View

16.

Wu J, Odman A, Higgins L, Haugk K, Vessella R, Ludwig D . In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res. 2005; 11(8):3065-74. DOI: 10.1158/1078-0432.CCR-04-1586. View

17.

Pollak M . Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8(12):915-28. DOI: 10.1038/nrc2536. View

18.

Fizazi K, Fizazi K, Higano C, Nelson J, Gleave M, Miller K . Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2013; 31(14):1740-7. DOI: 10.1200/JCO.2012.46.4149. View

19.

Engelman J . Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9(8):550-62. DOI: 10.1038/nrc2664. View

20.

Hong D, Bowles D, Falchook G, Messersmith W, George G, OBryant C . A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2012; 18(15):4173-82. DOI: 10.1158/1078-0432.CCR-12-0714. View